ZYNLONTA Shows Strong Clinical Results in LOTIS-7 Trial; ADC Therapeutics Stock Surges

GasFeeCrybaby · 2025-12-26T05:30:55+00:00

ADC Therapeutics is presenting an investor briefing on its LOTIS-7 trial for treatment-resistant diffuse large B-cell lymphoma, highlighting positive results from combinations of ZYNLONTA with other therapies, especially COLUMVI. The trial shows a promising overall response rate, leading to a rise in ADCT's stock.

GasFeeCrybaby

2025-12-26 05:30:55

Abstract generation in progress

ADC Therapeutics (ADCT) is set to deliver a comprehensive investor briefing this morning at 8:00 a.m. EST, focusing on the latest developments from its LOTIS-7 trial—a Phase 1b open-label investigation into combination therapies for treatment-resistant diffuse large B-cell lymphoma.

Trial Design and Drug Combinations

The LOTIS-7 study examines multiple therapeutic combinations centered on ZYNLONTA, the company’s proprietary antibody-drug conjugate. Primary combinations being evaluated include ZYNLONTA paired with Roche’s COLUMVI, alongside two additional regimens: ZYNLONTA with polatuzumab vedotin and ZYNLONTA with mosunetuzumab. The trial aims to establish both safety profiles and therapeutic efficacy in patients who have failed previous treatment options.

Impressive Clinical Data from EHA 2025

Recent findings unveiled at the European Hematology Association 2025 Congress in June provided compelling evidence for the ZYNLONTA plus COLUMVI combination. Among 30 patients with relapsed or refractory diffuse large B-cell lymphoma, the dual-drug approach achieved a 93.3% overall response rate, with 86.7% of patients achieving complete remission. These response metrics suggest significant clinical potential in a notoriously difficult-to-treat patient population.

Market Response

The positive trial momentum translated immediately into market performance, with ADCT closing Tuesday’s session at $4.60, representing an 8.49% gain. The stock movement reflects investor optimism regarding the clinical progress and potential commercial prospects of the ZYNLONTA platform in hematologic malignancies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.